{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:23:10Z","timestamp":1785252190786,"version":"3.55.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Metastasis to the pleural and peritoneal cavities is a common terminal pathway for a wide variety of cancers. This article explores how these unique environments both promote aggressive tumor behavior and suppresses anti-tumor immunity, and ways in which local delivery of protein therapeutics can leverage the contained nature of these spaces to a therapeutic advantage, achieving high intra-cavital concentrations while minimizing systemic toxicity.<\/jats:p>","DOI":"10.3389\/fimmu.2022.846235","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T07:26:41Z","timestamp":1644564401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity"],"prefix":"10.3389","volume":"13","author":[{"given":"Vera S.","family":"Donnenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Luketich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.","family":"Donnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important Prognostic Factors for Survival in Patients With Malignant Pleural Effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1164\/ajrccm.162.5.ats8-00","article-title":"Management of Malignant Pleural Effusions","volume":"162","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205285","article-title":"Predicting Survival in Malignant Pleural Effusion: Development and Validation of the LENT Prognostic Score","volume":"69","author":"Clive","year":"2014","journal-title":"Thorax"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl499","article-title":"Pattern and Prognostic Factors in Patients With Malignant Ascites: A Retrospective Study","volume":"18","author":"Ayantunde","year":"2007","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jso.25453","article-title":"Palliation of Malignant Ascites","volume":"120","author":"Hodge","year":"2019","journal-title":"J Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.022210","article-title":"Management of Malignant Bowel Obstruction Associated With GI Cancers","volume":"13","author":"Franke","year":"2017","journal-title":"J Oncol Pract"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27290","article-title":"Secretome of Pleural Effusions Associated With Non-Small Cell Lung Cancer (NSCLC) and Malignant Mesothelioma: Therapeutic Implications","volume":"10","author":"Donnenberg","year":"2019","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(19)30222-X","article-title":"The Secretome of Malignant Pleural Effusions: Clues to Targets of Therapy","volume":"85","author":"Donnenberg","year":"2019","journal-title":"Leukemia Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s42003-018-0180-x","article-title":"Mesothelial to Mesenchyme Transition as a Major Developmental and Pathological Player in Trunk Organs and Their Cavities","volume":"1","author":"Koopmans","year":"2018","journal-title":"Commun Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.25.1_supplement.1036.3","article-title":"Barrier Function of Human Pleura Mesothelium is Constituted by Tight Junctions","volume":"25","author":"Amasheh","year":"2011","journal-title":"FASEB J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40425-019-0590-4","article-title":"Treatment of Malignant Pleural Effusions: The Case for Localized Immunotherapy","volume":"7","author":"Donnenberg","year":"2019","journal-title":"J\u00a0ImmunoTher Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.501","article-title":"Intrapleural Administration of Interleukin 2 in Pleural Mesothelioma: A Phase I-II Study","volume":"72","author":"Goey","year":"1995","journal-title":"Br J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03635.x","article-title":"Pharmacokinetics, Immunogenicity and Bioactivity of the Therapeutic Antibody Catumaxomab Intraperitoneally Administered to Cancer Patients","volume":"69","author":"Ruf","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/CJI.0b013e318195b5bb","article-title":"Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM\u00d7Anti-CD3): Results of a Phase 1\/2\u00a0Study","volume":"32","author":"Sebastian","year":"2009","journal-title":"J Immunother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1","article-title":"A Framework for Advancing Our Understanding of Cancer-Associated Fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/thx.34.3.389","article-title":"Study of Immunoglobulins in Pleura and Pleural Effusions","volume":"34","author":"Telvi","year":"1979","journal-title":"Thorax"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17460441.2021.1978972","article-title":"Advances in mRNA-Based Drug Discovery in Cancer Immunotherapy","volume":"17","author":"Di \u2009Trani","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e3281c61a85","article-title":"Video Assisted Thoracoscopic Surgery and Lobectomy, Sublobar Resection, Radiofrequency Ablation, and Stereotactic Radiosurgery: Advances and Controversies in the Management of Early Stage non-Small Cell Lung Cancer","volume":"13","author":"Pennathur","year":"2007","journal-title":"Curr Opin Pulmonary Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(01)00980-2","article-title":"Laparoscopic Continuous Hyperthermic Peritoneal Perfusion1","volume":"193","author":"Chang","year":"2001","journal-title":"J Am Coll Surgeons"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2009.10.013","article-title":"The Minimum Anticipated Biological Effect Level (MABEL) for Selection of First Human Dose in Clinical Trials With Monoclonal Antibodies","volume":"20","author":"Muller","year":"2009","journal-title":"Curr Opin Biotechnol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12845","article-title":"Interleukin-2 Reverses CD8(+) T Cell Exhaustion in Clinical Malignant Pleural Effusion of Lung Cancer","volume":"186","author":"Hu","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A Phase I Clinical Trial of Single-Dose Intrapleural IFN-\u03b2 Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.amjsurg.2016.06.008","article-title":"Surgical Immune Interventions for Solid Malignancies","volume":"212","author":"Zeltsman","year":"2016","journal-title":"Am J Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of Metastatic Uveal Melanoma With Adoptive Transfer of Tumour-Infiltrating Lymphocytes: A Single-Centre, Two-Stage, Single-Arm, Phase 2 Study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13010","article-title":"Intrapleural Immunotherapy: An Update on Emerging Treatment Strategies for Pleural Malignancy","volume":"13","author":"Murthy","year":"2019","journal-title":"Clin Respir J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11912-021-01130-x","article-title":"A New Generation of Vaccines in the Age of Immunotherapy","volume":"23","author":"Addeo","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA Vaccine for Cancer Immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.11.3399","article-title":"Comparison of Toxicity and Survival Following Intraperitoneal Recombinant Interleukin-2 for Persistent Ovarian Cancer After Platinum: Twenty-Four-Hour Versus 7-Day Infusion","volume":"15","author":"Edwards","year":"1997","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12032-014-0076-7","article-title":"Catumaxomab With and Without Prednisolone Premedication for the Treatment of Malignant Ascites Due to Epithelial Cancer: Results of the Randomised Phase IIIb CASIMAS Study","volume":"31","author":"Sehouli","year":"2014","journal-title":"Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21604","article-title":"Resolution of Massive Pleural Effusion Due to Lymphoma With Intrapleural Interleukin-2","volume":"85","author":"Elkadi","year":"2010","journal-title":"Am J Hematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12967-021-02937-9","article-title":"PD-1\/PD-L1 Checkpoint Inhibitors During Late Stages of Life: An Ad-Hoc Analysis From a Large Multicenter Cohort","volume":"19","author":"Santini","year":"2021","journal-title":"J Transl Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccell.2021.11.002","article-title":"The Allergy Mediator Histamine Confers Resistance to Immunotherapy in Cancer Patients via Activation of the Macrophage Histamine Receptor H1","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09477-4","article-title":"Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies","volume":"28","author":"Ekeke","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02388","article-title":"The Role of TLRs in Anti-Cancer Immunity and Tumor Rejection","volume":"10","author":"Urban-Wojciuk","year":"2019","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5852.504-a","article-title":"Postoperative Empyema and Survival in Lung Cancer","volume":"1","author":"Bone","year":"1973","journal-title":"Br Med J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197211162872004","article-title":"Postoperative Empyema Improves Survival in Lung Cancer. Documentation and Analysis of a Natural Experiment","volume":"287","author":"Ruckdeschel","year":"1972","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(03)00067-X","article-title":"Novel IL-12 Family Members Shed Light on the Orchestration of Th1 Responses","volume":"24","author":"Brombacher","year":"2003","journal-title":"Trends Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000505099","article-title":"Interleukin-6: A Masterplayer in the Cytokine Network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The Pro- and Anti-Inflammatory Properties of the Cytokine Interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta (BBA)  Mol Cell Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199707270-00015","article-title":"Interleukin 6 and Interferon-Gamma Gene Expression in Lung Transplant Recipients With Refractory Acute Cellular Rejection: Implications for Monitoring and Inhibition by Treatment With Aerosolized Cyclosporine","volume":"64","author":"Iacono","year":"1997","journal-title":"Transplantation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.smim.2013.12.002","article-title":"Clinical Experience of IL-6 Blockade in Rheumatic Diseases\u2014Implications on IL-6 Biology and Disease Pathogenesis","volume":"26","author":"Davies","year":"2014","journal-title":"Semin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.d01-889.x","article-title":"IL-6 and Soluble IL-6 Receptors (sIL-6R and Sgp130) in Human Pleural Effusions: Massive IL-6 Production Independently of Underlying Diseases","volume":"107","author":"Dor\u00e9","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190450","article-title":"Tumor-Derived IL-6 and Trans-Signaling Among Tumor, Fat, and Muscle Mediate Pancreatic Cancer Cachexia","volume":"218","author":"Rupert","year":"2021","journal-title":"J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/0008-5472.CAN-10-1496","article-title":"IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer","volume":"71","author":"Lo","year":"2011","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3041","article-title":"A Breast Cancer Stem Cell Niche Supported by Juxtacrine Signalling From Monocytes and Macrophages","volume":"16","author":"Lu","year":"2014","journal-title":"Nat Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of Serious Infections in Tocilizumab Versus Other Biologic Drugs in Patients With Rheumatoid Arthritis: A Multidatabase Cohort Study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheumatic Dis"},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Trans Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"00026v1","DOI":"10.1073\/pnas.2005615117","article-title":"Effective Treatment of Severe COVID-19 Patients With Tocilizumab","author":"Xu","year":"2020","journal-title":"ChinaXiv"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.18.5.2909","article-title":"Histamine Affects Interleukin-4, Interleukin-5, and Interferon-Gamma Production by Human T Cell Clones From the Airways and Blood","volume":"18","author":"Krouwels","year":"1998","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S156708","article-title":"Critical Concepts in Adaptive Clinical Trials","volume":"10","author":"Park","year":"2018","journal-title":"Clin Epidemiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.846235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T07:26:44Z","timestamp":1644564404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.846235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2022.846235"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.846235","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"article-number":"846235"}}